• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Healthcare·TRABI.BO
Share

Transgene Biotek Limited Stocks

₹ 2.91Last Updated 30.07.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

₹ 2.39M

₹ 2.91
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Transgene Biotek Ltd. is a biotechnology enterprise focused on the development and commercialization of diagnostic kits. The company is also active in the manufacturing and oral formulation of diverse proteins through its distinctive TrabiORAL technology. Its array of products includes TrabiDHA, Tacrolimus, and Orlistat. K. Koteswara Rao established the firm in 1991, and its primary operations are based in Hyderabad, India.

Company Valuation

Fairly valued
4/7

From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

31.07.2026 15:23

Morning in New York: The "bulls" are back in the AI sector

31.07.2026 15:00

Apnimed IPO: A company backed by an investor in Uber, X, and Revolut has gone public

31.07.2026 14:44

Tesla May Sell Its China Business to Merge with SpaceX — WSJ. Musk Denies This

31.07.2026 14:28

Lessons for Wall Street: 6 Questions About Aschenbrenner, the “AI Nostradamus,” and the Collapse of His Fund

31.07.2026 14:00

A Focus on Kazakhstan, Copper, and Low Costs: Why Analysts Have Faith in Arras Minerals

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026